CARY STREET PARTNERS FINANCIAL LLC
Position in BBIO — BridgeBio Pharma, Inc.
CIK 1475045
RICHMOND, VA
Position in BBIO
as of Jun 30, 2026
· filed Jul 17, 2026
Position Value
$465,500
-$50,607 QoQ
Shares Held
6,250
-10.1% QoQ
Ownership
0.003%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#12
of 52 holders
Holding Since
Dec 2024
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in BBIO Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026CARY STREET PARTNERS FINANCIAL LLC holds $16,295,157 across 13 Biotechnology names. BBIO ranks #5 (2.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
22,571 | $11,211,692 | |
| 2 | HALO |
Halozyme Therapeutics, Inc.
|
20,445 | $1,600,230 | |
| 3 | DFTX |
Definium Therapeutics, Inc.
|
15,582 | $732,977 | |
| 4 | PGEN |
Precigen, Inc.
|
87,593 | $499,280 | |
| 5 | BBIO |
BridgeBio Pharma, Inc.
This page
|
6,250 | $465,500 | |
| 6 | CADL |
Candel Therapeutics, Inc.
|
43,100 | $443,930 | |
| 7 | DNTH |
Dianthus Therapeutics, Inc. /DE/
|
3,645 | $355,314 | |
| 8 | ONC |
BeOne Medicines Ltd.
|
986 | $280,980 |
All Filings in BBIO
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $465,500 | 6,250 | Shares | Defined | 2026-07-17 | |
| 2026-03-31 | $516,107 | 6,950 | Shares | Defined | 2026-04-29 | |
| 2025-12-31 | $531,605 | 6,950 | Shares | Defined | 2026-02-09 | |
| 2025-09-30 | $386,953 | 7,450 | Shares | Defined | 2025-11-10 | |
| 2025-06-30 | $332,486 | 7,700 | Shares | Defined | 2025-08-13 | |
| 2025-03-31 | $266,189 | 7,700 | Shares | Defined | 2025-05-09 | |
| 2024-12-31 | $531,238 | 19,360 | Shares | Defined | 2025-02-14 | |
| No filing history on record for this holder in this stock. | ||||||